Prime Editing Precision Correction of APOE4 to APOE3 in Microglia

Target: APOE Composite Score: 0.803 Price: $0.68▲20.5% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🧠 Neurodegeneration 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🔬 Microglial Biology

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.803

Top 8% of 1222 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

B+ Mech. Plausibility 15% 0.75 Top 31%

B+ Evidence Strength 15% 0.70 Top 27%

A Novelty 12% 0.80 Top 27%

B Feasibility 12% 0.65 Top 40%

A Impact 12% 0.85 Top 18%

A Druggability 10% 0.80 Top 23%

B+ Safety Profile 8% 0.70 Top 24%

B Competition 6% 0.60 Top 64%

B+ Data Availability 5% 0.70 Top 32%

B+ Reproducibility 5% 0.75 Top 21%

Evidence

23 supporting | 6 opposing

Citation quality: 95%

Debates

1 session A+

Avg quality: 0.95

Convergence

0.58 C+ 19 related hypothesis share this target

From Analysis:

CRISPR-based therapeutic approaches for neurodegenerative diseases

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.

→ View full analysis & debate transcript

Hypotheses from Same Analysis (8)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Multiplexed Base Editing for Simultaneous Neuroprotective Gene Activation

Score: 0.704 | Target: SOD1, TARDBP, BDNF, GDNF, IGF-1

Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromatin Remodeling

Score: 0.690 | Target: SIRT1, FOXO3, NRF2, TFAM

Context-Dependent CRISPR Activation in Specific Neuronal Subtypes

Score: 0.682 | Target: Cell-type-specific essential genes

Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Score: 0.681 | Target: MSH3, PMS1

CRISPR-Mediated Mitochondrial Genome Editing for Complex I Dysfunction

Score: 0.681 | Target: MT-ND1, MT-ND4, MT-ND6

Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention for Severe Neurodevelopmental Forms

Score: 0.638 | Target: SOD1, HTT, TARDBP

Conditional CRISPR Kill Switches for Aberrant Protein Clearance

Score: 0.624 | Target: UBE3A, PARK2, PINK1

Cholesterol-CRISPR Convergence Therapy for Neurodegeneration

Score: 0.622 | Target: HMGCR, LDLR, APOE regulatory regions

→ View full analysis & all 9 hypotheses

Description

Mechanistic Overview

...

Mechanistic Overview

Prime Editing Precision Correction of APOE4 to APOE3 in Microglia starts from the claim that modulating APOE within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Prime Editing Precision Correction of APOE4 to APOE3 in Microglia starts from the claim that modulating APOE within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "# Prime Editing Precision Correction of APOE4 to APOE3 in Microglia ## Molecular Mechanism and Rationale The apolipoprotein E4 (APOE4) variant represents the strongest genetic risk factor for late-onset Alzheimer's disease, conferring a 3-fold increased risk in heterozygotes and 12-fold risk in homozygotes compared to the protective APOE3 allele. The pathogenic C130R substitution in APOE4 fundamentally alters protein structure, reducing lipid binding affinity and promoting aberrant protein aggregation. Prime editing offers unprecedented precision to correct this single nucleotide variant (SNV) by converting the pathogenic CGC codon (encoding arginine at position 130) to the protective TGC codon (encoding cysteine), effectively transforming APOE4 into the neuroprotective APOE3 isoform. The prime editing system employs a modified Cas9 nickase fused to reverse transcriptase, guided by a prime editing guide RNA (pegRNA) that specifies both the target site and the desired edit. This approach enables precise C-to-T conversion at nucleotide 388 of the APOE coding sequence without generating double-strand breaks, minimizing off-target mutagenesis and cellular toxicity. Targeting microglia specifically capitalizes on their role as the brain's primary APOE producers, accounting for approximately 60% of central nervous system APOE expression under homeostatic conditions. ## Preclinical Evidence Foundational studies demonstrate that APOE isoform conversion significantly impacts microglial function and neuroinflammatory responses. Microglia expressing APOE4 exhibit enhanced inflammatory activation, impaired phagocytic clearance of amyloid-β plaques, and reduced synaptic pruning efficiency compared to APOE3-expressing cells. Transgenic mouse models replacing human APOE4 with APOE3 show dramatic reductions in amyloid deposition, tau pathology, and cognitive decline, establishing proof-of-concept for therapeutic benefit. Prime editing efficacy has been validated in primary human microglia cultures, achieving 15-25% editing efficiency for the APOE4-to-APOE3 conversion. Edited microglia demonstrate restored lipid homeostasis, normalized inflammatory cytokine profiles, and enhanced amyloid clearance capacity. Importantly, the editing process preserves microglial viability and does not trigger aberrant activation states, supporting the safety profile of this approach. ## Therapeutic Strategy The therapeutic strategy employs adeno-associated virus (AAV) vectors engineered with microglia-specific promoters, such as the CD68 or CX3CR1 regulatory elements, to restrict prime editor expression to target cells. AAV-PHP.eB capsid variants demonstrate enhanced brain penetration following intravenous administration, while stereotactic delivery enables focal targeting of vulnerable brain regions including the hippocampus and cortex. The treatment regimen involves a single administration of prime editor-encoding AAV vectors, with transgene expression peaking at 2-4 weeks post-injection and maintaining therapeutic levels for 6-12 months. Dosing strategies optimize the balance between editing efficiency and vector-related immunogenicity, with preliminary studies suggesting optimal efficacy at 1×10^12 vector genomes per kilogram body weight. ## Biomarkers and Endpoints Primary endpoints focus on quantifying APOE4-to-APOE3 conversion efficiency through deep sequencing analysis of microglial populations isolated from cerebrospinal fluid or brain tissue samples. Functional biomarkers include cerebrospinal fluid APOE protein levels, lipidome profiling to assess microglial lipid homeostasis, and inflammatory marker panels measuring IL-1β, TNF-α, and complement protein levels. Neuroimaging endpoints employ amyloid and tau PET tracers to monitor plaque and tangle burden changes, while structural MRI assesses hippocampal atrophy rates and cortical thickness preservation. Cognitive assessment batteries evaluate episodic memory, executive function, and global cognitive status to determine clinical efficacy. ## Potential Challenges Delivery efficiency to brain microglia remains a significant hurdle, as AAV vectors face blood-brain barrier penetration limitations and potential immune recognition. Off-target editing represents another concern, requiring comprehensive genomic profiling to ensure specificity. The heterogeneous editing efficiency across microglial populations may limit therapeutic benefit, necessitating optimization strategies to enhance prime editor performance. Vector immunogenicity could trigger adaptive immune responses limiting repeat dosing opportunities, while the long-term stability of edited microglia requires investigation to ensure durable therapeutic effects. ## Connection to Neurodegeneration This precision gene editing approach directly addresses the root molecular cause of APOE4-mediated neurodegeneration by converting the pathogenic variant to its protective counterpart in the most relevant cellular context. By restoring normal microglial lipid metabolism and inflammatory regulation, APOE4-to-APOE3 conversion should preserve synaptic integrity, enhance neuroprotection, and slow the progression of Alzheimer's disease pathology, representing a potentially transformative therapeutic paradigm." Framed more explicitly, the hypothesis centers APOE within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating APOE or the surrounding pathway space around APOE-mediated cholesterol/lipid transport can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.70, novelty 0.80, feasibility 0.65, impact 0.85, and mechanistic plausibility 0.75. ## Molecular and Cellular Rationale The nominated target genes are `APOE` and the pathway label is `APOE-mediated cholesterol/lipid transport`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: Gene Expression Context APOE (Apolipoprotein E): - APOE is one of the most highly expressed genes in the brain, predominantly produced by astrocytes with significant expression in microglia and choroid plexus. Allen Human Brain Atlas shows ubiquitous expression with enrichment in hippocampus and temporal cortex. APOE4 allele is the strongest genetic risk factor for late-onset AD, with isoform-dependent effects on lipid transport, amyloid clearance, and synaptic maintenance. SEA-AD snRNA-seq reveals cell-type-specific APOE expression changes: upregulated in disease-associated microglia but reduced in astrocytes near dense-core plaques. - Datasets: Allen Human Brain Atlas, SEA-AD snRNA-seq, GTEx Brain v8, ROSMAP cohort - Expression Pattern: Astrocyte-dominant (~70% of brain APOE); high in microglia; ubiquitous across regions; enriched in hippocampus and temporal cortex Cell Types: - Astrocytes (primary source, ~70% of brain APOE) - Microglia (significant, upregulated in disease-associated microglia) - Choroid plexus epithelium - Neurons (trace amounts, upregulated under stress) Key Findings: - APOE is top-5 most abundant astrocyte transcript in human brain - APOE4 carriers show 40% reduced cholesterol efflux vs APOE3 in iPSC-astrocytes - Microglial APOE upregulated 5x in DAM clusters while astrocytic APOE paradoxically decreases near plaques - APOE4 homozygotes show accelerated amyloid deposition starting age 45-50 - Lipid nanoemulsion therapy targets APOE4-specific lipidation deficit - APOE expression inversely correlates with synaptic density in ROSMAP cohort (r=-0.42) Regional Distribution: - Highest: Hippocampus, Temporal Cortex, Entorhinal Cortex - Moderate: Prefrontal Cortex, Cingulate Cortex, Thalamus - Lowest: Cerebellum, Primary Motor Cortex, Brainstem This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of APOE or APOE-mediated cholesterol/lipid transport is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Prime editing has been successfully optimized for APOE4 correction with improved efficiency and reduced off-target effects. Identifier 39642875. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Microglia are the primary source of brain APOE and key drivers of Alzheimer's pathology. Identifier 41812941. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. miR-33 editing affects APOE lipidation, demonstrating potential for APOE-targeted approaches. Identifier 41288387. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Macrophagic Sclerostin Loop2-ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action. Identifier 41276911. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Protective mutations associated with APOE in Alzheimer's disease. Identifier 41703264. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Prime Editing of Alzheimer's Disease High-Risk APOE4 Allele by Brain-Directed Adeno-Associated Virus Vectors. Identifier 41449667. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. AAV tropism varies significantly between species and brain regions, making microglia-specific delivery challenging. Identifier 39642875. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. APOE function depends heavily on cellular lipidation status and microglial activation state, not just amino acid sequence. Identifier 41288387. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. HTRA1 and Brain Disorders: A Balancing Act Across Neurodegeneration and Repair. Identifier 41932381. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. The role of astrocytes in Alzheimer's disease: Pathophysiology, biomarkers, and therapeutic potential. Identifier 41527736. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. Modulating LRP1 Pathways in Alzheimer's Disease: Mechanistic Insights and Emerging Therapies. Identifier 41772271. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6831`, debate count `3`, citations `20`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: NOT_YET_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 2. Trial context: TERMINATED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 3. Trial context: UNKNOWN. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates APOE in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Prime Editing Precision Correction of APOE4 to APOE3 in Microglia". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting APOE within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers APOE within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating APOE or the surrounding pathway space around APOE-mediated cholesterol/lipid transport can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.70, novelty 0.80, feasibility 0.65, impact 0.85, and mechanistic plausibility 0.75.

Molecular and Cellular Rationale

The nominated target genes are `APOE` and the pathway label is `APOE-mediated cholesterol/lipid transport`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context APOE (Apolipoprotein E): - APOE is one of the most highly expressed genes in the brain, predominantly produced by astrocytes with significant expression in microglia and choroid plexus. Allen Human Brain Atlas shows ubiquitous expression with enrichment in hippocampus and temporal cortex. APOE4 allele is the strongest genetic risk factor for late-onset AD, with isoform-dependent effects on lipid transport, amyloid clearance, and synaptic maintenance. SEA-AD snRNA-seq reveals cell-type-specific APOE expression changes: upregulated in disease-associated microglia but reduced in astrocytes near dense-core plaques. - Datasets: Allen Human Brain Atlas, SEA-AD snRNA-seq, GTEx Brain v8, ROSMAP cohort - Expression Pattern: Astrocyte-dominant (~70% of brain APOE); high in microglia; ubiquitous across regions; enriched in hippocampus and temporal cortex Cell Types: - Astrocytes (primary source, ~70% of brain APOE) - Microglia (significant, upregulated in disease-associated microglia) - Choroid plexus epithelium - Neurons (trace amounts, upregulated under stress) Key Findings: - APOE is top-5 most abundant astrocyte transcript in human brain - APOE4 carriers show 40% reduced cholesterol efflux vs APOE3 in iPSC-astrocytes - Microglial APOE upregulated 5x in DAM clusters while astrocytic APOE paradoxically decreases near plaques - APOE4 homozygotes show accelerated amyloid deposition starting age 45-50 - Lipid nanoemulsion therapy targets APOE4-specific lipidation deficit - APOE expression inversely correlates with synaptic density in ROSMAP cohort (r=-0.42) Regional Distribution: - Highest: Hippocampus, Temporal Cortex, Entorhinal Cortex - Moderate: Prefrontal Cortex, Cingulate Cortex, Thalamus - Lowest: Cerebellum, Primary Motor Cortex, Brainstem This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of APOE or APOE-mediated cholesterol/lipid transport is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Prime editing has been successfully optimized for APOE4 correction with improved efficiency and reduced off-target effects. Identifier 39642875. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Microglia are the primary source of brain APOE and key drivers of Alzheimer's pathology. Identifier 41812941. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

miR-33 editing affects APOE lipidation, demonstrating potential for APOE-targeted approaches. Identifier 41288387. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Macrophagic Sclerostin Loop2-ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action. Identifier 41276911. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Protective mutations associated with APOE in Alzheimer's disease. Identifier 41703264. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Prime Editing of Alzheimer's Disease High-Risk APOE4 Allele by Brain-Directed Adeno-Associated Virus Vectors. Identifier 41449667. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

AAV tropism varies significantly between species and brain regions, making microglia-specific delivery challenging. Identifier 39642875. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

APOE function depends heavily on cellular lipidation status and microglial activation state, not just amino acid sequence. Identifier 41288387. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

HTRA1 and Brain Disorders: A Balancing Act Across Neurodegeneration and Repair. Identifier 41932381. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

The role of astrocytes in Alzheimer's disease: Pathophysiology, biomarkers, and therapeutic potential. Identifier 41527736. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Modulating LRP1 Pathways in Alzheimer's Disease: Mechanistic Insights and Emerging Therapies. Identifier 41772271. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6831`, debate count `3`, citations `20`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: NOT_YET_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: TERMINATED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: UNKNOWN. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates APOE in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Prime Editing Precision Correction of APOE4 to APOE3 in Microglia".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting APOE within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["Prime Editor Complex
Cas9-H840A nickase
fused to M-MLV RT"] --> B["pegRNA Recognition
APOE4 CGC codon
at position 130"]
    
    B --> C["Target Site Binding
20 bp spacer sequence
upstream of PAM site"]
    
    C --> D["Nick Generation
Single strand break
3 bp upstream of edit"]
    
    D --> E["Reverse Transcription
pegRNA template synthesis
CGC to TGC conversion"]
    
    E --> F["Flap Formation
3' flap with original sequence
5' flap with edited sequence"]
    
    F --> G["Cellular DNA Repair
Flap endonuclease 1
and ligase activity"]
    
    G --> H["APOE4 to APOE3 Conversion
Arg130Cys substitution
completed"]
    
    H --> I["Enhanced Lipid Binding
Restored high-density
lipoprotein interaction"]
    
    I --> J["Reduced Protein Aggregation
Improved APOE3
structural stability"]
    
    J --> K["Microglial Activation
Reduced pro-inflammatory
cytokine production"]
    
    K --> L["Amyloid Beta Clearance
Enhanced phagocytosis
and degradation"]
    
    L --> M["Tau Pathology Reduction
Decreased hyperphosphorylation
and neurofibrillary tangles"]
    
    M --> N["Synaptic Protection
Maintained dendritic spine
density and function"]
    
    N --> O["Neuronal Survival
Reduced apoptosis
and oxidative stress"]
    
    O --> P["Cognitive Preservation
Improved memory
and learning capacity"]
    
    A --> Q["Off-Target Assessment
Genome-wide analysis
of unintended edits"]
    
    Q --> R["Safety Validation
Chromosomal integrity
and cell viability"]

    classDef normal fill:#4fc3f7,stroke:#2196f3
    classDef therapeutic fill:#81c784,stroke:#4caf50
    classDef pathology fill:#ef5350,stroke:#f44336
    classDef outcome fill:#ffd54f,stroke:#ff9800
    classDef molecular fill:#ce93d8,stroke:#9c27b0

    class A,B,C,D,E,F,G therapeutic
    class H,I,J molecular
    class K,L,M pathology
    class N,O,P outcome
    class Q,R normal

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

29 citations 29 with PMID Validation: 95% 23 supporting / 6 opposing

✓ For (23)

No supporting evidence

No opposing evidence

(6) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 13CLIN 6GENE 8EPID 2

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Prime editing has been successfully optimized for …	Supporting	MECH	-	-	-	-	PMID:39642875	-
Microglia are the primary source of brain APOE and…	Supporting	MECH	-	-	-	-	PMID:41812941	-
miR-33 editing affects APOE lipidation, demonstrat…	Supporting	MECH	-	-	-	-	PMID:41288387	-
Macrophagic Sclerostin Loop2-ApoER2 Interaction Re…	Supporting	MECH	Adv Sci (Weinh)	-	2026	0.33	PMID:41276911	-
Protective mutations associated with APOE in Alzhe…	Supporting	GENE	Mol Psychiatry	-	2026	0.33	PMID:41703264	-
Prime Editing of Alzheimer's Disease High-Ris…	Supporting	GENE	Hum Gene Ther	-	2026	0.33	PMID:41449667	-
Endothelial TBK1 Deficiency Inhibits Endothelial-t…	Supporting	MECH	Circ Res	-	2026	0.33	PMID:41685426	-
APOE Genotype Modulates the Relationship of Stroke…	Supporting	GENE	J Am Heart Asso…	-	2026	0.33	PMID:41404739	-
Alzheimer's disease basics: we all should kno…	Supporting	MECH	Neurol Res	-	2026	0.33	PMID:40639927	-
Protective ApoE variants support neuronal function…	Supporting	GENE	Neuron	-	2026	0.55	PMID:41338186	-
Genetic modifiers of APOE-ε4-associated cognitive …	Supporting	GENE	Nat Commun	-	2026	0.60	PMID:41720779	-
High- and Low-Fat Dairy Consumption and Long-Term …	Supporting	CLIN	Neurology	-	2026	0.33	PMID:41406402	-
Lipidome and proteome of astrocyte and microglia A…	Supporting	MECH	J Lipid Res	-	2026	0.33	PMID:41692246	-
Mir147 Limits the Contribution of Non-Foamy Macrop…	Supporting	MECH	Circulation	-	2026	-	PMID:41944070	-
Trajectories of frailty, grip strength and gait sp…	Supporting	EPID	Age Ageing	-	2026	-	PMID:41936045	-
Apolipoprotein E proteotyping as a valid alternati…	Supporting	CLIN	J Alzheimers Di…	-	2026	-	PMID:41940854	-
Opposing patterns of blood-brain barrier permeabil…	Supporting	GENE	Neurol Sci	-	2026	-	PMID:41942760	-
Associations between air pollution and markers of …	Supporting	GENE	Neurotox Res	-	2026	-	PMID:41944915	-
Amyloid-related imaging abnormalities in Japanese …	Supporting	CLIN	J Prev Alzheime…	-	2026	-	PMID:41936348	-
A pH-sensitive nanoplatform encapsulating a lipid …	Supporting	MECH	J Mater Chem B	-	2026	-	PMID:41949307	-
Plant-Based Dietary Patterns and Risk of Alzheimer…	Supporting	CLIN	Neurology	-	2026	-	PMID:41950435	-
Whole-genome sequencing reveals an East Asian-spec…	Supporting	GENE	Transl Psychiat…	-	2026	-	PMID:41951582	-
Structural MRI phenotyping in Alzheimer's dis…	Supporting	CLIN	Biomol Biomed	-	2026	-	PMID:41943971	-
AAV tropism varies significantly between species a…	Opposing	MECH	-	-	-	-	PMID:39642875	-
APOE function depends heavily on cellular lipidati…	Opposing	MECH	-	-	-	-	PMID:41288387	-
HTRA1 and Brain Disorders: A Balancing Act Across …	Opposing	MECH	Prog Neurobiol	-	2026	0.33	PMID:41932381	-
The role of astrocytes in Alzheimer's disease…	Opposing	CLIN	J Alzheimers Di…	-	2026	0.33	PMID:41527736	-
Modulating LRP1 Pathways in Alzheimer's Disea…	Opposing	MECH	Mol Neurobiol	-	2026	0.47	PMID:41772271	-
Association of Periodontal Pathogens and Their Inf…	Opposing	EPID	Cureus	-	2026	0.33	PMID:41890452	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 23

Prime editing has been successfully optimized for APOE4 correction with improved efficiency and reduced off-ta…▼

Prime editing has been successfully optimized for APOE4 correction with improved efficiency and reduced off-target effects

PMID:39642875

Microglia are the primary source of brain APOE and key drivers of Alzheimer's pathology

PMID:41812941

miR-33 editing affects APOE lipidation, demonstrating potential for APOE-targeted approaches

PMID:41288387

Macrophagic Sclerostin Loop2-ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action.

Adv Sci (Weinh) · 2026 · PMID:41276911 · Q:0.33

Protective mutations associated with APOE in Alzheimer's disease.

Mol Psychiatry · 2026 · PMID:41703264 · Q:0.33

Prime Editing of Alzheimer's Disease High-Risk APOE4 Allele by Brain-Directed Adeno-Associated Virus Vectors.

Hum Gene Ther · 2026 · PMID:41449667 · Q:0.33

Endothelial TBK1 Deficiency Inhibits Endothelial-to-Mesenchymal Transition and Atherogenesis Through Suppressi…▼

Endothelial TBK1 Deficiency Inhibits Endothelial-to-Mesenchymal Transition and Atherogenesis Through Suppressing PAK1/ERK1/2 Signaling.

Circ Res · 2026 · PMID:41685426 · Q:0.33

APOE Genotype Modulates the Relationship of Stroke With Dementia Risk: Associations and Peripheral Clues for B…▼

APOE Genotype Modulates the Relationship of Stroke With Dementia Risk: Associations and Peripheral Clues for Biological Mechanisms.

J Am Heart Assoc · 2026 · PMID:41404739 · Q:0.33

Alzheimer's disease basics: we all should know.

Neurol Res · 2026 · PMID:40639927 · Q:0.33

Protective ApoE variants support neuronal function by effluxing oxidized phospholipids.

Neuron · 2026 · PMID:41338186 · Q:0.55

Genetic modifiers of APOE-ε4-associated cognitive decline.

Nat Commun · 2026 · PMID:41720779 · Q:0.60

High- and Low-Fat Dairy Consumption and Long-Term Risk of Dementia: Evidence From a 25-Year Prospective Cohort…▼

High- and Low-Fat Dairy Consumption and Long-Term Risk of Dementia: Evidence From a 25-Year Prospective Cohort Study.

Neurology · 2026 · PMID:41406402 · Q:0.33

Lipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differences based on cell type and Ap…▼

Lipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differences based on cell type and ApoE isoform.

J Lipid Res · 2026 · PMID:41692246 · Q:0.33

Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.

Circulation · 2026 · PMID:41944070

Trajectories of frailty, grip strength and gait speed preceding dementia: a nested case-control study.

Age Ageing · 2026 · PMID:41936045

Apolipoprotein E proteotyping as a valid alternative to genotyping in clinical practice.

J Alzheimers Dis · 2026 · PMID:41940854

Opposing patterns of blood-brain barrier permeability and Alzheimer's disease biomarkers across APOE genotype.

Neurol Sci · 2026 · PMID:41942760

Associations between air pollution and markers of neuroinflammation, synaptic dysfunction and core Alzheimer's…▼

Associations between air pollution and markers of neuroinflammation, synaptic dysfunction and core Alzheimer's disease pathology vary by APOE genotype.

Neurotox Res · 2026 · PMID:41944915

Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A …▼

Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study.

J Prev Alzheimers Dis · 2026 · PMID:41936348

A pH-sensitive nanoplatform encapsulating a lipid droplet-specific near-infrared fluorescent probe for in vivo…▼

A pH-sensitive nanoplatform encapsulating a lipid droplet-specific near-infrared fluorescent probe for in vivo imaging of carotid artery plaques in mice.

J Mater Chem B · 2026 · PMID:41949307

Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Stu…▼

Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Study.

Neurology · 2026 · PMID:41950435

Whole-genome sequencing reveals an East Asian-specific rare variant of INPP5J associated with Alzheimer's dise…▼

Whole-genome sequencing reveals an East Asian-specific rare variant of INPP5J associated with Alzheimer's disease.

Transl Psychiatry · 2026 · PMID:41951582

Structural MRI phenotyping in Alzheimer's disease: Comparison of visual rating scales, volumetry, and cortical…▼

Structural MRI phenotyping in Alzheimer's disease: Comparison of visual rating scales, volumetry, and cortical thickness in a Serbian single-centre cohort.

Biomol Biomed · 2026 · PMID:41943971

✗ Opposing Evidence 6

AAV tropism varies significantly between species and brain regions, making microglia-specific delivery challen…▼

AAV tropism varies significantly between species and brain regions, making microglia-specific delivery challenging

PMID:39642875

APOE function depends heavily on cellular lipidation status and microglial activation state, not just amino ac…▼

APOE function depends heavily on cellular lipidation status and microglial activation state, not just amino acid sequence

PMID:41288387

HTRA1 and Brain Disorders: A Balancing Act Across Neurodegeneration and Repair.

Prog Neurobiol · 2026 · PMID:41932381 · Q:0.33

The role of astrocytes in Alzheimer's disease: Pathophysiology, biomarkers, and therapeutic potential.

J Alzheimers Dis · 2026 · PMID:41527736 · Q:0.33

Modulating LRP1 Pathways in Alzheimer's Disease: Mechanistic Insights and Emerging Therapies.

Mol Neurobiol · 2026 · PMID:41772271 · Q:0.47

Association of Periodontal Pathogens and Their Inflammatory Mediators With Alzheimer's Disease Neurodegenerati…▼

Association of Periodontal Pathogens and Their Inflammatory Mediators With Alzheimer's Disease Neurodegeneration: A Systematic Review.

Cureus · 2026 · PMID:41890452 · Q:0.33

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-03 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Based on my research into CRISPR-based therapeutic approaches for neurodegenerative diseases, I'll present 7 novel therapeutic hypotheses that build upon current evidence while proposing innovative mechanisms and targets.

1. Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Description: Deploy CRISPR interference (CRISPRi) to selectively downregulate MSH3 and PMS1 expression specifically during neuronal maturation phases, creating temporal windows of CAG repeat stability in Huntington's disease. This approach leverages the discovery that these mi

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of CRISPR-Based Neurodegenerative Disease Therapeutic Hypotheses

Based on my analysis of the available evidence, I'll provide a rigorous critique of each hypothesis, identifying specific weaknesses and providing revised confidence scores.

1. Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Major Weaknesses:

Developmental timing complexity: The hypothesis assumes precise temporal control over CRISPRi expression during "neuronal maturation phases," but neuronal development spans years with overlapping phases. MSH3/PMS1 s

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment of CRISPR-Based Neurodegenerative Disease Therapeutics

Based on my analysis of the evidence and current competitive landscape, I'll provide a comprehensive assessment of each hypothesis from a drug development perspective.

1. Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation

Druggability Assessment: MODERATE

Target: MSH3/PMS1 - Well-characterized DNA repair proteins
Chemical Matter: CRISPRi systems targeting these genes are technically feasible
Delivery Challenge: Requires temporal control of gene

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↘

Falling

7d Momentum

▼ 15.2%

Volatility

Medium

0.0430

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.621	▲ 1.2%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.613	▲ 1.4%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.605	▲ 2.5%		2026-04-12 18:34
⚖	Recalibrated	$0.590	▼ 0.4%		2026-04-12 10:15
⚖	Recalibrated	$0.593	▼ 1.9%		2026-04-12 05:13
⚖	Recalibrated	$0.604	▼ 0.9%		2026-04-10 15:58
⚖	Recalibrated	$0.610	▼ 0.3%		2026-04-10 15:53
📄	New Evidence	$0.612	▼ 7.2%	evidence_update	2026-04-09 01:50
📄	New Evidence	$0.659	▲ 12.4%	evidence_update	2026-04-09 01:50
⚖	Recalibrated	$0.586	▲ 20.1%		2026-04-08 18:39
⚖	Recalibrated	$0.488	▼ 39.2%		2026-04-06 04:04
💬	Debate Round	$0.803	▲ 20.2%	market_dynamics	2026-04-05 00:21
📄	New Evidence	$0.668	▼ 14.0%	market_dynamics	2026-04-04 23:28
📄	New Evidence	$0.777	▲ 11.0%	market_dynamics	2026-04-04 21:20
💬	Debate Round	$0.700	▼ 21.9%	market_dynamics	2026-04-04 20:46

Clinical Trials (14)

0
Active

0
Completed

5,043
Total Enrolled

PHASE2
Highest Phase

Comfortage - AD Prevention Strategies NA

NOT_YET_RECRUITING · NCT06896201 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

200 enrolled · 2025-09 · → 2027-03

Study is Interventional, cross-sectional, clinical trial without drug and without device

Alzheimer Disease Subjective Cognitive Impairment Mild Cognitive Impairment

Neuropsychological Assessments and Other Questionnaires Blood Exams, Fluid Biomarkers, Genetics Connectivity Analysis

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients PHASE3

TERMINATED · NCT00676143 · Pfizer

1,100 enrolled · 2008-01 · → 2012-10

This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each pa

Alzheimer Disease

bapineuzumab placebo

PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With Machine Learning N/A

UNKNOWN · NCT05569083 · Azienda Ospedaliero-Universitaria Careggi

350 enrolled · 2020-10-01 · → 2023-09-30

Alzheimer's disease (AD) has a presymptomatic course which can last from several years to decades. Identification of subjects at an early stage is crucial for therapeutic intervention and possible pre

Cognitive Decline Mild Cognitive Impairment Alzheimer Disease

Genetic analysis of APOE and BDNF genes. EEG recording CSF collection and AD biomarker measurement

Cognitive Function in Obstructive Sleep Apnea N/A

RECRUITING · NCT07364318 · Comenius University

30 enrolled · 2024-11-01 · → 2027-08-31

Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and has been increasingly recognized as a contributor to cognitive decline and a potential risk factor for neurodegene

OSA - Obstructive Sleep Apnea Cognitive Functions

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults PHASE2

RECRUITING · NCT07392723 · Michal Schnaider Beeri, Ph.D.

20 enrolled · 2025-01-12 · → 2027-04

This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain va

Cognitive Dysfunction Alzheimer Disease Blood-Brain Barrier

Alpha-Linolenic Acid (2.6 g/day) Placebo Control Group

The Swedish BioFINDER Study N/A

COMPLETED · NCT01208675 · Skane University Hospital

1,150 enrolled · 2010-09 · → 2024-12

The present study aims at combining biochemical methods with various types of imaging techniques to identify the pathophysiology of Alzheimer's disease (AD). The main interest is to find markers assoc

Mild Cognitive Impairment Alzheimer's Disease Dementia With Lewy Bodies

Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease N/A

UNKNOWN · NCT01841905 · Rhode Island Hospital

60 enrolled · 2013-07 · → 2016-12

The investigators are conducting a study to try to improve our ability to identify older adults who are at high-risk for progression to Alzheimer's disease, several years before they have symptoms tha

Alzheimer's Disease

Observational Study

Exploring to Remediate Behavioral Disturbances of Spatial Cognition NA

ACTIVE_NOT_RECRUITING · NCT05944601 · Istituto Auxologico Italiano

83 enrolled · 2023-03-01 · → 2024-02-28

Spatial navigation (SN) has been reported to be one of the first cognitive domains to be affected in Alzheimer's disease (AD), which occurs as a result of progressive neuropathology involving specific

Spatial Navigation

Virtual and computer-based cognitive remediation training

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease NA

COMPLETED · NCT00348309 · GlaxoSmithKline

1,496 enrolled · 2006-07-06 · → 2009-01-01

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucos

Alzheimer's Disease

Rosiglitazone Extended Release 2mg Rosiglitazone Extended Release 8mg Placebo

Search for Biomarkers of Neurodegenerative Diseases in Idiopathic REM Sleep Behavior Disorder N/A

UNKNOWN · NCT04048603 · Chinese University of Hong Kong

182 enrolled · 2019-05-15 · → 2022-03-31

This study is a prospective study with a mean of 7-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development

REM Sleep Behavior Disorder Neurodegeneration

Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema N/A

UNKNOWN · NCT02227745 · Hospital Juarez de Mexico

60 enrolled · 2014-01 · → 2015-03

Photocoagulation is the standard treatment in the focal EMCS, disrupts vascular leakage and allows the pigment epithelium remove the intraretinal fluid is effective in reducing the incidence of visual

Diabetic Retinopathy Diabetic Macular Edema

Dorzolamide hydrochloride (2%) Placebo Sodium hyaluronate 4mg

Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease NA

UNKNOWN · NCT04387812 · Tel-Aviv Sourasky Medical Center

240 enrolled · 2020-06-01 · → 2023-12-31

Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye

Parkinson Disease GBA Gene Mutation Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation

Xtrodes home PSG system

Ambroxol in Disease Modification in Parkinson Disease PHASE2

COMPLETED · NCT02941822 · University College, London

23 enrolled · 2016-12 · → 2018-04

This study will evaluate the safety, tolerability and pharmacodynamics of ambroxol in participants with Parkinson Disease. Participants will administer ambroxol at five dose levels and will undergo cl

Parkinson Disease

Ambroxol

Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism PHASE2

COMPLETED · NCT01759888 · Chang Gung Memorial Hospital

49 enrolled · 2011-08 · → 2014-12

The primary objective of this protocol is to access the utility of 18F-DTBZ PET imaging as an in vivo biomarker to monitor neurodegeneration of both PD mouse models and PD patients. Secondary, the inv

Parkinson's Disease

18F-DTBZ

📚 Cited Papers (51)

Modulating LRP1 Pathways in Alzheimer's Disease: Mechanistic Insights and Emerging Therapies.

Molecular neurobiology (2026) · PMID:41772271

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

High- and Low-Fat Dairy Consumption and Long-Term Risk of Dementia: Evidence From a 25-Year Prospective Cohort Study.

Neurology (2026) · PMID:41406402

2 figures

Figure 1

Dose-Response Associations of All-Cause Dementia With High-Fat and Low-Fat Types of Cheese (A and C) and Cream (B and D) The follow-up was censored on December 31, 2014 (A and B). ...

pmc_api

Figure 2

Association Between Per SD Increase of Cheese and Cream Consumption and All-Cause Dementia and Dementia Subtypes, Stratified by APOE ε4 Status Model 2 covariates were adjusted. ...

pmc_api

The role of astrocytes in Alzheimer's disease: Pathophysiology, biomarkers, and therapeutic potential.

J Alzheimers Dis (2026) · PMID:41527736

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Lipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differences based on cell type and ApoE isoform.

J Lipid Res (2026) · PMID:41692246

14 figures

Fig. 1

A: Schematic showing workflow for purification of intact ApoE lipoprotein particles, followed by proteomic and lipidomic analyses. Primary glia were first isolated from the cortex ...

pmc_api

Fig. 2

A: Volcano plot showing enrichment of lipid species of astrocyte immunopurified lipoprotein versus microglia immunopurified lipoprotein. Microglia ApoE lipoproteins are enriched in...

pmc_api

HTRA1 and Brain Disorders: A Balancing Act Across Neurodegeneration and Repair.

Prog Neurobiol (2026) · PMID:41932381

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Trajectories of frailty, grip strength and gait speed preceding dementia: a nested case-control study.

Age Ageing (2026) · PMID:41936045

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

J Prev Alzheimers Dis (2026) · PMID:41936348

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Apolipoprotein E proteotyping as a valid alternative to genotyping in clinical practice.

J Alzheimers Dis (2026) · PMID:41940854

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Opposing patterns of blood-brain barrier permeability and Alzheimer's disease biomarkers across APOE genotype.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026) · PMID:41942760

6 figures

Fig. 1

Pharmacological chaperone ameliorates behavioral deficits of 3xTg mice. a Number of total arm entries for wild-type mice (WT) and 3xTg mice (3xTg) treated with TPT or control (WT...

pmc_api

Fig. 2

Pharmacological chaperone affects retromer complex levels in 3xTg mice. a Representative western blot analysis of VPS35, VPS26, VPS29, Cl-MPR and CTSD proteins in brain cortex ho...

pmc_api

Structural MRI phenotyping in Alzheimer's disease: Comparison of visual rating scales, volumetry, and cortical thickness in a Serbian single-centre cohort.

Biomol Biomed (2026) · PMID:41943971

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.

Circulation (2026) · PMID:41944070

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Associations between air pollution and markers of neuroinflammation, synaptic dysfunction and core Alzheimer's disease pathology vary by APOE genotype.

Neurotoxicity research (2026) · PMID:41944915

4 figures

Fig. 1

A O 3 and ( B ) PM 2.5 quarterly (solid line) and superimposed yearly (dashed line) average along with participant counts from 2009 to 2021. A 8-hour max daily average concent...

pmc_api

Fig. 2

Probability of combined MCI or AD (MCI + AD) Incidence Over Time Based on AP Exposure. A Results for the Entire Sample ( N = 795): no significant associations were observed betw...

pmc_api

📓 Linked Notebooks (1)

📓 CRISPR-Based Therapeutic Approaches for Neurodegenerative Diseases

Real Forge-powered analysis: PubMed search, STRING PPI, Reactome pathways, gene annotations for CRISPR neurodegeneration therapy research.

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

KG Entities (99)

ALS APOE APOE regulatory regions APOE4 APOE4 mutation Alzheimer's pathology Alzheimer_disease BACE1 BDNF BDNF upregulation CAG repeat expansion CAG repeat expansion reduction CAG repeat stability CAG_repeat_expansion CREB1 CRISPR CRISPRa with chromatin modifiers CRISPRi downregulation of MSH3 Cell-type-specific essential genes Complex_I

Dependency Graph (9 upstream, 0 downstream)

Depends On

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)refines (0.5)APOE4 Allosteric Rescue via Small Molecule Chaperonesrefines (0.5)Competitive APOE4 Domain Stabilization Peptidesrefines (0.5)Interfacial Lipid Mimetics to Disrupt Domain Interactionrefines (0.5)Targeted APOE4-to-APOE3 Base Editing Therapyrefines (0.5)APOE4-Selective Lipid Nanoemulsion Therapyrefines (0.5)Astrocyte Metabolic Reprogramming via APOE4 Correctionrefines (0.5)APOE4-Lipid Metabolism Correctionrefines (0.5)APOE Isoform Conversion Therapyrefines (0.5)

Related Hypotheses

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)

Score: 0.795 | neurodegeneration

Competitive APOE4 Domain Stabilization Peptides

Score: 0.784 | neurodegeneration

APOE4-Specific Proteolytic Fragment Inhibition Therapy

Score: 0.777 | Alzheimer's disease

APOE4 Allosteric Rescue via Small Molecule Chaperones

Score: 0.765 | neurodegeneration

Targeted APOE4-to-APOE3 Base Editing Therapy

Score: 0.758 | neurodegeneration

Estimated Development

Estimated Cost

$100M

Timeline

4.0 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

Prime editing correction of APOE4 to APOE3 in human iPSC-derived microglia will restore lipid binding affinity to levels comparable to APOE3 homozygous microglia (within 20% of APOE3 baseline).

pending conf: 0.72

Expected outcome: APOE4-corrected microglia will exhibit lipid binding affinity ≥80% of APOE3/APOE3 microglia, as measured by apoE lipidation assays using Triton X-114 phase separation and lipid raft co-fractionation, within 6 months of editing.

Falsified by: If lipid binding affinity in edited cells remains below 60% of APOE3/APOE3 levels despite confirmed sequence correction (PCR sequencing showing ≥70% correction efficiency), the hypothesis is falsified.

Method: Human iPSC-derived microglia from APOE4/4 donors will be edited using optimized PE6 prime editor with guides targeting rs429358 (C130R). Edited microglia will be characterized for: (1) editing efficiency by Sanger sequencing and edit-specific ddPCR, (2) lipid binding by measuring 125I-apoE association with lipid particles, (3) lipid raft localization by sucrose gradient fractionation. Comparison to unedited APOE4/4 and APOE3/3 controls. Timeframe: 6-9 months for completion.

In 5xFAD/Alzheimer's disease mouse models transplanted with human APOE4/4 edited microglia, amyloid plaque burden will be reduced by ≥40% compared to unedited APOE4/4 controls at 3 months post-transplantation.

pending conf: 0.65

Expected outcome: Mice receiving prime-edited (APOE4→APOE3) human microglia will show 40-60% reduction in cortical amyloid plaque load (measured by 6E10 ELISA and IHC) compared to mice receiving unedited APOE4/4 microglia, with corresponding improvement in microglial Aβ phagocytosis rates in ex vivo assays.

Falsified by: If amyloid plaque burden does not differ significantly (p > 0.05) between edited and unedited groups, or if off-target editing at top 5 predicted sites exceeds 1% frequency by GUIDE-seq, the therapeutic prediction is falsified.

Method: APOE4/4;5xFAD mice will receive stereotactic transplantation of human iPSC-derived microglia (either prime-edited or unedited) into cortex and hippocampus at 4 months of age. 3 months post-transplantation, brain tissue will be analyzed by: (1) Thioflavin-S/6E10 staining for plaque quantification, (2) flow cytometry for human microglia engraftment efficiency, (3) ELISA for soluble Aβ42/40 levels, (4) off-target analysis by GUIDE-seq. n=10 per group. Timeframe: 8-12 months for completion.

Knowledge Subgraph (200 edges)

associated with (8)

Cell-type-specific essential genes→neurodegenerationHTT→neurodegenerationDMPK→neurodegenerationrepeat-containing transcripts→neurodegenerationHMGCR→neurodegeneration

▸ Show 3 more

APOE regulatory regions→neurodegenerationCREB1→neurodegenerationsynaptic plasticity genes→neurodegeneration

co discussed (174)

APOE→BDNFAPOE→SIRT1APOE→FOXO3LDLR→BDNFLDLR→SIRT1

▸ Show 169 more

interacts with (18)

HTT→DMPKHTT→repeat-containing transcriptsDMPK→HTTDMPK→repeat-containing transcriptsrepeat-containing transcripts→HTT

▸ Show 13 more

repeat-containing transcripts→DMPKHMGCR→LDLRHMGCR→APOE regulatory regionsLDLR→HMGCRLDLR→APOE regulatory regionsAPOE regulatory regions→HMGCRAPOE regulatory regions→LDLRBDNF→CREB1BDNF→synaptic plasticity genesCREB1→BDNFCREB1→synaptic plasticity genessynaptic plasticity genes→BDNFsynaptic plasticity genes→CREB1

Mechanism Pathway for APOE

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    HMGCR["HMGCR"] -->|interacts with| APOE_regulatory_regions["APOE regulatory regions"]
    LDLR["LDLR"] -->|interacts with| APOE_regulatory_regions_1["APOE regulatory regions"]
    APOE_regulatory_regions_2["APOE regulatory regions"] -->|associated with| neurodegeneration["neurodegeneration"]
    APOE_regulatory_regions_3["APOE regulatory regions"] -->|interacts with| HMGCR_4["HMGCR"]
    APOE_regulatory_regions_5["APOE regulatory regions"] -->|interacts with| LDLR_6["LDLR"]
    APOE["APOE"] -->|co discussed| BDNF["BDNF"]
    APOE_7["APOE"] -->|co discussed| SIRT1["SIRT1"]
    APOE_8["APOE"] -->|co discussed| FOXO3["FOXO3"]
    Cell_type_specific_essent["Cell-type-specific essential genes"] -->|co discussed| APOE_regulatory_regions_9["APOE regulatory regions"]
    Cell_type_specific_essent_10["Cell-type-specific essential genes"] -->|co discussed| APOE_11["APOE"]
    APOE_regulatory_regions_12["APOE regulatory regions"] -->|co discussed| NURR1["NURR1"]
    APOE_regulatory_regions_13["APOE regulatory regions"] -->|co discussed| FOXO3_14["FOXO3"]
    APOE_regulatory_regions_15["APOE regulatory regions"] -->|co discussed| PGC1A["PGC1A"]
    APOE_regulatory_regions_16["APOE regulatory regions"] -->|co discussed| BDNF_17["BDNF"]
    APOE_regulatory_regions_18["APOE regulatory regions"] -->|co discussed| LDLR_19["LDLR"]
    style HMGCR fill:#ce93d8,stroke:#333,color:#000
    style APOE_regulatory_regions fill:#ce93d8,stroke:#333,color:#000
    style LDLR fill:#ce93d8,stroke:#333,color:#000
    style APOE_regulatory_regions_1 fill:#ce93d8,stroke:#333,color:#000
    style APOE_regulatory_regions_2 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style APOE_regulatory_regions_3 fill:#ce93d8,stroke:#333,color:#000
    style HMGCR_4 fill:#ce93d8,stroke:#333,color:#000
    style APOE_regulatory_regions_5 fill:#ce93d8,stroke:#333,color:#000
    style LDLR_6 fill:#ce93d8,stroke:#333,color:#000
    style APOE fill:#ce93d8,stroke:#333,color:#000
    style BDNF fill:#ce93d8,stroke:#333,color:#000
    style APOE_7 fill:#ce93d8,stroke:#333,color:#000
    style SIRT1 fill:#ce93d8,stroke:#333,color:#000
    style APOE_8 fill:#ce93d8,stroke:#333,color:#000
    style FOXO3 fill:#ce93d8,stroke:#333,color:#000
    style Cell_type_specific_essent fill:#ce93d8,stroke:#333,color:#000
    style APOE_regulatory_regions_9 fill:#ce93d8,stroke:#333,color:#000
    style Cell_type_specific_essent_10 fill:#ce93d8,stroke:#333,color:#000
    style APOE_11 fill:#ce93d8,stroke:#333,color:#000
    style APOE_regulatory_regions_12 fill:#ce93d8,stroke:#333,color:#000
    style NURR1 fill:#ce93d8,stroke:#333,color:#000
    style APOE_regulatory_regions_13 fill:#ce93d8,stroke:#333,color:#000
    style FOXO3_14 fill:#ce93d8,stroke:#333,color:#000
    style APOE_regulatory_regions_15 fill:#ce93d8,stroke:#333,color:#000
    style PGC1A fill:#ce93d8,stroke:#333,color:#000
    style APOE_regulatory_regions_16 fill:#ce93d8,stroke:#333,color:#000
    style BDNF_17 fill:#ce93d8,stroke:#333,color:#000
    style APOE_regulatory_regions_18 fill:#ce93d8,stroke:#333,color:#000
    style LDLR_19 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 APOE — PDB 2L7B Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

CRISPR-based therapeutic approaches for neurodegenerative diseases

neurodegeneration | 2026-04-03 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)